Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2004 in Healthy Subjects
NCT05369767Phase 1Unknown
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- May 2022
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in arterial thrombosis and venous thrombosis comparing SAD, SHR-2004 with SAD, SHR-2004 placebo (2 arms). Primary endpoint: Number of subjects with adverse events (AEs) and serious adverse events (SAEs). Status: unknown.
02
Drugs
SHR-2004
03
Conditions
arterial thrombosisvenous thrombosis
Beyond the preview
Go deeper on NCT05369767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369767.